These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

Clozapine is often referred to as the gold standard for the treatment of schizophrenia and yet
has also been described as the most underutilized treatment for schizophrenia supported by …

Background. When schizophrenia patients have insufficient response to clozapine,
pharmacological augmentation is often applied. This meta-analysis summarizes available …

Objective: Clozapine is the preferred option for treatment-resistant schizophrenia. However,
since 1975, clozapine has been known to cause agranulocytosis. In the clozapine screening …

BACKGROUND: Clozapine is widely prescribed for treatment refractory patients with
schizophrenia, but its use is limited by potentially life threatening adverse effects …

Psychiatric co-morbidity among substance users refers to the simultaneous presence of at
least another psychiatric disorder in a person diagnosed with a substance use disorder. Co …

Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second
antipsychotic–a metaanalysis. Objective: To examine using metaanalysis the effect of …

Hyperprolactinaemia is a common side effect of antipsychotics; markedly raised levels are
less common. Higher levels of prolactin result from longer exposure to higher doses …

Obsessive-compulsive disorder (OCD) is rarely associated with schizophrenia, whereas 20
to 30% of schizophrenic patients, suffer from comorbid obsessive-compulsive symptoms …